GlobeImmune Inc
GlobeImmune, Inc., a biopharmaceutical company, focuses on developing therapeutic products for cancer and infectious diseases based on proprietary Tarmogen platforms. The company's product candidate includes GS-4774, which is in Phase 2 trials for the treatment of patients with chronically infected with hepatitis B virus, as well as with oral antiviral suppressive therapy. The company is also inv… Read more
GlobeImmune Inc (GBIM) - Net Assets
Latest net assets as of March 2016: $2.15 Million USD
Based on the latest financial reports, GlobeImmune Inc (GBIM) has net assets worth $2.15 Million USD as of March 2016.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($9.77 Million) and total liabilities ($7.62 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $2.15 Million |
| % of Total Assets | 22.01% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
GlobeImmune Inc - Net Assets Trend (2010–2015)
This chart illustrates how GlobeImmune Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for GlobeImmune Inc (2010–2015)
The table below shows the annual net assets of GlobeImmune Inc from 2010 to 2015.
| Year | Net Assets | Change |
|---|---|---|
| 2015-12-31 | $2.99 Million | -46.67% |
| 2014-12-31 | $5.60 Million | +102.81% |
| 2013-12-31 | $-199.32 Million | -1.63% |
| 2012-12-31 | $-196.12 Million | -7.53% |
| 2011-12-31 | $-182.40 Million | -15.65% |
| 2010-12-31 | $-157.72 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to GlobeImmune Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 6775272100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2015)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $5.75K | 0.19% |
| Other Comprehensive Income | $-9.80 Million | -327.91% |
| Other Components | $238.25 Million | 7972.61% |
| Total Equity | $2.99 Million | 100.00% |
GlobeImmune Inc Competitors by Market Cap
The table below lists competitors of GlobeImmune Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
OXB
KLSE:0368
|
$575.13 |
|
J A Textile Mills Ltd
KAR:JATM
|
$575.35 |
|
Renewable Innovations Inc.
OTCQB:REII
|
$575.46 |
|
LETLOLE LA RONA LIMITED
XBOT:LETS-EQO
|
$575.57 |
|
O.T. Mining Corp
PINK:OTMN
|
$574.48 |
|
PIT
WAR:PIT
|
$573.93 |
|
VENUS METALS
BE:EZL
|
$573.90 |
|
Aquawalk Group Berhad
KLSE:0380
|
$572.78 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in GlobeImmune Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2014 to 2015, total equity changed from 5,603,491 to 2,988,400, a change of -2,615,091 (-46.7%).
- Net loss of 2,766,905 reduced equity.
- Other comprehensive income decreased equity by 9,799,287.
- Other factors increased equity by 9,951,101.
Equity Change Factors (2014 to 2015)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-2.77 Million | -92.59% |
| Other Comprehensive Income | $-9.80 Million | -327.91% |
| Other Changes | $9.95 Million | +332.99% |
| Total Change | $- | -46.67% |
Book Value vs Market Value Analysis
This analysis compares GlobeImmune Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.00x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2010-12-31 | $-1649.37 | $0.00 | x |
| 2011-12-31 | $-1907.48 | $0.00 | x |
| 2012-12-31 | $-2051.04 | $0.00 | x |
| 2013-12-31 | $-2084.48 | $0.00 | x |
| 2014-12-31 | $1.92 | $0.00 | x |
| 2015-12-31 | $0.52 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently GlobeImmune Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -92.59%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -42.85%
- • Asset Turnover: 0.56x
- • Equity Multiplier: 3.85x
- Recent ROE (-92.59%) is below the historical average (-75.37%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2010 | 0.00% | -363.63% | 0.17x | 0.00x | $979.92K |
| 2011 | 0.00% | -290.87% | 0.29x | 0.00x | $3.38 Million |
| 2012 | 0.00% | -13.76% | 3.45x | 0.00x | $17.60 Million |
| 2013 | 0.00% | 42.08% | 3.04x | 0.00x | $29.41 Million |
| 2014 | -359.63% | -337.75% | 0.32x | 3.28x | $-20.71 Million |
| 2015 | -92.59% | -42.85% | 0.56x | 3.85x | $-3.07 Million |
Industry Comparison
This section compares GlobeImmune Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| GlobeImmune Inc (GBIM) | $2.15 Million | 0.00% | 3.54x | $575.00 |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |